Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in HD patients. Methods One hundred and thir...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama, Michiaki Usui, Michio Chiba, Atsuo Moriyama, Atsuko Ohara, Hiroshi Miyazaki, Tatsuyuki Kakuma, Kei Fukami
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2020-12-01
Series:	Renal Replacement Therapy
Assuntos:	Cinacalcet Etelcalcetide Hemodialysis Intact-PTH Secondary hyperparathyroidism
Acceso en liña:	https://doi.org/10.1186/s41100-020-00310-y
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!